These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35191936)

  • 1. HIV and Hepatitis C Virus Testing and Treatment Services in Specialty Treatment Facilities That Offer Medication for Opioid Use Disorder in the US.
    Patel EU; Genberg BL; Zhu X; Krawczyk N; Mehta SH; Tobian AAR
    JAMA; 2022 Feb; 327(8):776-777. PubMed ID: 35191936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs.
    Bachhuber MA; Cunningham CO
    JAMA; 2013 Dec; 310(24):2671-2. PubMed ID: 24368468
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H
    J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provision of and Barriers to Integrating Reproductive and Sexual Health Services for Reproductive-age Women in Opioid Treatment Programs.
    Klaman SL; Lorvick J; Jones HE
    J Addict Med; 2019; 13(6):422-429. PubMed ID: 31689259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients.
    Kresina TF; Eldred L; Bruce RD; Francis H
    AIDS; 2005 Oct; 19 Suppl 3():S221-6. PubMed ID: 16251822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urgent need for HIV and hepatitis prevention in drug treatment programs in Hungary.
    Gyarmathy VA; Rácz J; Neaigus A; Ujhelyi E
    AIDS Educ Prev; 2004 Jun; 16(3):276-87. PubMed ID: 15237056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    BMC Public Health; 2016 Jul; 16():666. PubMed ID: 27473519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Testing and Counseling at U.S. Substance Use Treatment Facilities: A Missed Opportunity for Early Identification.
    Riano NS; Borowsky HM; Arnold EA; Olfson M; Walkup JT; Vittinghoff E; Cournos F; Dawson L; Bazazi AR; Crystal S; Mangurian C
    Psychiatr Serv; 2021 Dec; 72(12):1385-1391. PubMed ID: 34126780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs.
    Brown LS; Kritz S; Goldsmith RJ; Bini EJ; Robinson J; Alderson D; Rotrosen J
    Public Health Rep; 2007; 122(4):441-51. PubMed ID: 17639646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
    Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
    J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    J Subst Abuse Treat; 2016 Apr; 63():46-53. PubMed ID: 26810130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.
    Frimpong JA; D'Aunno T; Jiang L
    Am J Public Health; 2014 Jun; 104(6):e75-82. PubMed ID: 24825236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coalition seeks funding for HCV/HIV co-infection. Integrating services makes economic, medical sense.
    AIDS Alert; 2003 May; 18(5):63-5. PubMed ID: 12751456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missed opportunities for hepatitis C testing in opioid treatment programs.
    Frimpong JA
    Am J Public Health; 2013 Jun; 103(6):1028-30. PubMed ID: 23597374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of U.S. Substance Abuse Treatment Facilities Offering HIV Services: Results From a National Survey.
    Cohn A; Stanton C; Elmasry H; Ehlke S; Niaura R
    Psychiatr Serv; 2016 Jun; 67(6):692-5. PubMed ID: 26975517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carceral limb of the public body: jail inmates, prisoners, and infectious disease.
    Comfort ML; Grinstead O
    J Int Assoc Physicians AIDS Care (Chic); 2004; 3(2):45-8. PubMed ID: 15346689
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
    Carey KJ; Huang W; Linas BP; Tsui JI
    J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Geography of Opioid Use Disorder: A Data Triangulation Approach.
    Sullivan PS; Bradley HM; Rio CD; Rosenberg ES
    Infect Dis Clin North Am; 2020 Sep; 34(3):451-464. PubMed ID: 32782095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaps in the drug-free and methadone treatment program response to Hepatitis C.
    Strauss SM; Astone J; Vassilev ZP; Des Jarlais DC; Hagan H
    J Subst Abuse Treat; 2003 Jun; 24(4):291-7. PubMed ID: 12867202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.